Arcturus Therapeutics (NASDAQ: ARCT), which previously had a “sell” rating, was given a “hold” recommendation by equity research analysts at StockNews.com in a note to investors that were published on Wednesday.
There have been several different analysts that have provided their commentary on the stock. In a research note published on Wednesday, November 2nd, Cantor Fitzgerald increased their price objective on Arcturus Therapeutics stock from $39.00 to $44.00. They also assigned the company an “overweight” rating. Arcturus Therapeutics was moved from a “neutral” rating to a “buy” rating by Citigroup in a research report published on Thursday, November 3rd. Additionally, Citigroup increased its price goal for the company from $22.00 to $35.00. Raymond James lowered their recommendation for Arcturus Therapeutics from “market perform” to “underperform” in a research report published on August 10th. Arcturus Therapeutics’ stock was given a reaffirmation of a “buy” recommendation by Brookline Capital Management in a research report that was published on August 10th.
Last but not least, Robert W. Baird lowered their recommendation on Arcturus Therapeutics, moving it from “neutral” to “underperform” and setting their price objective at $18.00. In a report distributed on Thursday, November 10th, three research experts recommended selling the stock, two who suggested holding onto it, and four who suggested purchasing it. According to Bloomberg, the stock is presently rated “Hold,” Market analysts anticipate it will reach a price of $28.25 shortly.
The NASDAQ: ARCT stock started trading at $16.19 on Wednesday. The moving average for the company over the past fifty days is $16.64, and the moving average for the past 200 days is $16.84. The firm’s market capitalization is currently sitting at $428.92 million, with a P/E ratio of -2.91 and a beta of 2.51. There is a debt-to-equity ratio of 0.22; the quick ratio is 3.25; the current ratio is also 3.25, and the quick ratio is 3.25. Arcturus Therapeutics has seen a low of $11.70 and a high of $48.75 over the past year in terms of the share price.
A few hedge funds have recently been active in the market, buying and selling ARCT shares. In the first three months of 2018, Daiwa Securities Group Inc. boosted the percentage of its ownership in Arcturus Therapeutics by 44.0%. Following the acquisition of an additional 1,071 shares during the preceding quarter, Daiwa Securities Group Inc. currently holds 3,503 shares of the stock held by the biotechnology business. The value of these shares is $94,000. Formidable Asset Management LLC grew its ownership of Arcturus Therapeutics by 8.5% over the year’s first three months. Formidable Asset Management LLC’s stock in the biotechnology firm is now valued at $379,000 following the acquisition of an additional 1,100 shares during the most recent quarter. The total number of shares that the company holds is 14,050. Nikko Asset Management Americas Inc. boosted the percentage of the company’s stock in Arcturus Therapeutics by 3.3% during the first quarter. Nikko Asset Management Americas Inc. now owns 1,402,078 shares of the biotechnology company’s stock, valued at $37,856,000 following purchasing 44,606 additional shares in the most recent quarter. During the first three months of 2018, IndexIQ Advisors LLC made a purchase of Arcturus Therapeutics for the amount of $382,000.00. Last but not least, during the first three months of the year, Los Angeles Capital Management LLC bought a new investment in Arcturus Therapeutics valued at around $1,608,000. Hedge funds and other institutional investors own 83.55% of the company’s stock.
Arcturus Therapeutics Holdings Inc., an RNA medicine company established in the United States, is primarily concerned with researching and producing vaccines for rare forms of infectious, hepatic, and respiratory disorders. LUNAR-CF studies cystic fibrosis lung illness caused by CFTR gene mutations; LUNAR-OTC studies ornithine transcarbamylase (OTC) deficiency; LUNAR-COV19 and LUNAR-FLU are studies of vaccines, and LUNAR-OTC is a study of ornithine transcarbamylase (OTC) deficiency.